Showing results (1-10 of 397) with videos related to
Sort By:
Pageof 40
Cardiovascular & Hematological Disorders Drug Targets|September 27, 2021
Endovascular Therapies for Type B Aortic DissectionRakhee R Makhija, Debabrata MukherjeeAnnals of Internal Medicine|February 2, 2026
In AF with drug-eluting stent for ≥1 y, NOACs were noninferior to NOAC + clopidogrel for a composite of adverse clinical events at 1 yDebabrata Mukherjee, Annals of Internal Medicine|August 18, 2020
After revascularization for PAD, rivaroxaban reduced vascular events with a small increase in major bleedingDebabrata MukherjeeAnnals of Internal Medicine|September 4, 2023
In HF, with or without PAD, dapagliflozin reduced a composite of worsening HF or CV death and did not increase amputationsDebabrata MukherjeeBiochemical Pharmacology|March 26, 2002
Selective cyclooxygenase-2 (COX-2) inhibitors and potential risk of cardiovascular eventsDebabrata MukherjeeCardiovascular & Hematological Agents in Medicinal Chemistry|December 15, 2012
Cardiovascular and Hematological Medicine in 2013 - Advances and InsightsDebabrata MukherjeeCongestive Heart Failure (Greenwich, Conn.)|April 11, 2008
Nonsteroidal anti-inflammatory drugs and the heart: what is the danger?Debabrata MukherjeeAnnals of Internal Medicine|September 2, 2024
In patients with NSTE-ACS and previous CABG, routine invasive vs. conservative management does not improve outcomesDebabrata MukherjeeCardiology Clinics|February 8, 2005
Percutaneous coronary intervention versus coronary artery bypass grafting in diabetic patientsDebabrata MukherjeeThrombosis and Haemostasis|September 28, 2006
Does a coxib-associated thrombotic risk limit the clinical use of the compounds as analgesic anti-inflammatory drugs? Arguments in favorDebabrata MukherjeePageof 40